Abstracts tagged "rheumatoid arthritis (RA) and safety"

Abstract Number: 1732 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety Of Subcutaneous Administration Of Tabalumab, An Anti-B Cell Activating Factor Monoclonal Antibody, In Rheumatoid Arthritis: Results From a Phase 3 Multicenter, Randomized, Double-Blind Study
MC Genovese¹, Gregg J. Silverman², Paul Emery³, Ramesh Gupta⁴, Anne Gill⁵, Wendy J. Komocsar⁵, Melissa Veenhuizen⁵, Li Xie⁵, Pierre-Yves Berclaz⁵ and Chin Lee⁵, ¹Division of Rheumatology, Stanford University, Palo Alto, CA, ²Rheumatology, NYU School of Medicine, New York, NY, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁴Private Practice, Memphis, TN, ⁵Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Tabalumab is a monoclonal antibody that neutralizes membrane-bound and soluble B cell activating factor (BAFF). These interim analyses evaluated the efficacy and safety of…
Abstract Number: 1413 • 2013 ACR/ARHP Annual Meeting
Long-Term Safety and Efficacy Of Certolizumab Pegol In Combination With Methotrexate In The Treatment Of Rheumatoid Arthritis: 5-Year Results From a 52-Week Randomized Controlled Trial and Open-Label Extension Study
Edward Keystone¹, Robert Landewé², Ronald van Vollenhoven³, Bernard Combe⁴, Vibeke Strand⁵, Philip J. Mease⁶, Laura Shaughnessy⁷, Brenda VanLunen⁷ and Désirée van der Heijde⁸, ¹University of Toronto, Toronto, ON, Canada, ²Academic Medical Center Amsterdam & Atrium Medical Center, Heerlen, Netherlands, ³Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, ⁴Montpellier University Hospital, Montpellier, France, ⁵Adjunct, Division of Immunology / Rheumatology, Stanford University, Palo Alto, CA, ⁶Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, ⁷UCB Pharma, Raleigh, NC, ⁸Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: In the RAPID1 randomized controlled trial (RCT; NCT00152386),1 certolizumab pegol (CZP) every 2 weeks (Q2W) plus MTX over 52 weeks (wks) provided rapid improvements…
Abstract Number: 1045 • 2013 ACR/ARHP Annual Meeting
Under Reporting Of Cataracts In Randomised Controlled Trials Investigating The Use Of Systemic Glucocorticoids In Patients With Rheumatoid Arthritis
Rachel J. Black^1,2 and William G. Dixon³, ¹Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ²Department of Medicine, The University of Adelaide, Adelaide, Australia, ³The University of Manchester, Manchester, United Kingdom
Background/Purpose: Oral glucocorticoid (GC) therapy is used in more than half of patients with rheumatoid arthritis (RA). Cataracts are a recognised treatment-related side effect of…
Abstract Number: 1573 • 2012 ACR/ARHP Annual Meeting
Baseline Screening Recommendations for Rheumatoid Arthritis Patients Treated with Disease Modifying Anti-Rheumatic Drugs: Does an Educational Intervention Change Practice in an Outpatient Clinic?
Debra C. Lloyd¹, John N. Mecchella² and Daniel Albert³, ¹Rheumatology, Dartmouth-Hitchcock Med Ctr, Lebanon, NH, ²Rheumatology, Dartmouth Hitchcock Medical Center, Lebanon, NH, ³Rheumatology, Dartmouth-Hitchcock Medical Center, Geisel School of Medicine, Lebanon, NH
Background/Purpose: In 2008, the American College of Rheumatology (ACR) developed recommendations for use of non-biologic and biologic DMARDs in the treatment of rheumatoid arthritis (RA). …
Abstract Number: 486 • 2012 ACR/ARHP Annual Meeting
Impact of Adalimumab Therapy On Laboratory Parameters of Interest in Patients with Early or Long-Standing Rheumatoid Arthritis
Daniel Furst¹, Ana P. Lacerda², Nupun Andhivarothai³, Jasmina Kalabic⁴ and Neelufar Mozaffarian³, ¹David Geffen School of Medicine, Div of Rheumatology, University of California at Los Angeles, Los Angeles, CA, ²Abbott Laboratories, São Paulo, Brazil, ³Abbott Laboratories, Abbott Park, IL, ⁴Abbott GmbH & Co. KG, Ludwigshafen, Germany
Background/Purpose: The systemic inflammation of rheumatoid arthritis (RA) can have detrimental effects on the hematopoietic and cardiovascular systems. Additionally, effective DMARD treatments for RA can…
Abstract Number: 342 • 2012 ACR/ARHP Annual Meeting
Novel Combination Therapy of Existing Repurposed Therapies, Designed by Predictive Software Modeling, Shows Profound Impact On Disease Progression in a Murine Collagen-Induced Arthritis Model
Shireen Vali¹, Canio Refino², Jay Dela Cruz², Robinson Vidva¹, Prashant Nair¹, Saumya Radhakrishnan¹, Pradeep Fernandes¹, Taher Abbasi¹ and Gurkirpal Singh³, ¹CellWorks Group, Saratoga, CA, ²InTouch Bio, Alameda, CA, ³Gastroenterology/Hepatology, Stanford University School of Medicine, Palo Alto, CA
Background/Purpose: Rheumatoid Arthritis (RA) involves a complex interaction of multiple cell systems, cytokines and mediators. We recently developed a predictive software-based mathematical model that emulates…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].